These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 3360871)

  • 1. High-performance liquid chromatographic method for the determination of a cyclandelate metabolite, mandelic acid, in human plasma.
    Kojima K; Uezono Y; Takahashi T; Nakanishi Y
    J Chromatogr; 1988 Mar; 425(1):203-7. PubMed ID: 3360871
    [No Abstract]   [Full Text] [Related]  

  • 2. Determination of plasma concentrations of cyclandelate and mandelic acid in patients with generalized atherosclerotic vasculopathy treated with oral cyclandelate.
    Forconi S; Cappelli R; Guerrini M; Volpi L; Frigerio C; Di Perri T
    J Int Med Res; 1990; 18(4):266-72. PubMed ID: 2227073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New determination of cyclandelate in plasma (author's transl)].
    Andermann G; Dietz M; Mergel D
    J Pharm Belg; 1979; 34(4):233-7. PubMed ID: 501515
    [No Abstract]   [Full Text] [Related]  

  • 4. Simultaneous determination of cyclandelate and its metabolite in human plasma by capillary column gas-liquid chromatography.
    Andermann G; Dietz M
    J Chromatogr; 1981 May; 223(2):365-70. PubMed ID: 7251791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of food on the bioavailability of cyclandelate from commercial capsules.
    Kaniwa N; Ogata H; Aoyagi N; Ejima A; Takahashi T; Uezono Y; Imazato Y
    Clin Pharmacol Ther; 1991 Jun; 49(6):641-7. PubMed ID: 2060253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioavailability of cyclandelate from capsules in beagle dogs and dissolution rate: correlations with bioavailability in humans.
    Kaniwa N; Ogata H; Aoyagi N; Ejima A; Takahashi T; Uezono Y; Imasato Y
    J Pharmacobiodyn; 1991 Mar; 14(3):152-60. PubMed ID: 1880705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative gas chromatographic mass spectrometric determination of mandelic acid in blood plasma. Comparison of deuterated and homologous internal standards.
    Luthe H; Ludwig-Köhn H; Langenbeck U
    Biomed Mass Spectrom; 1983 Mar; 10(3):183-6. PubMed ID: 6850070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of human platelet aggregation by cyclandelate.
    Van den Hoven WE; Hall DW
    Br J Clin Pract Suppl; 1984; 34():34-8. PubMed ID: 6430321
    [No Abstract]   [Full Text] [Related]  

  • 9. [Metabolites of cyclandelate. Vasodilator action and inhibition of phosphodiesterase by metabolites of cyclandelate].
    Himber J; De Burlet G; Andermann G
    Ann Pharm Fr; 1987; 45(3):233-41. PubMed ID: 3434974
    [No Abstract]   [Full Text] [Related]  

  • 10. [A thin-layer chromatography method for determining the styrene metabolites mandelic and phenylglyoxylic acid in urine].
    Gartzke J; Burck D
    Z Gesamte Hyg; 1989 Jun; 35(6):361-3. PubMed ID: 2800635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers.
    Hughes KM; Lang JC; Lazare R; Gordon D; Stanton SL; Malone-Lee J; Geraint M
    Xenobiotica; 1992 Jul; 22(7):859-69. PubMed ID: 1455904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The anti-hypoxaemic effect of cyclandelate in man measured in human volunteers using computer-assisted oculodynamic methodology.
    Schaffler K
    Br J Clin Pract Suppl; 1984; 34():51-7. PubMed ID: 6430324
    [No Abstract]   [Full Text] [Related]  

  • 13. [Stability of cyclandelate in a soft capsule].
    Richard J; Andermann G
    Pharm Acta Helv; 1982; 57(4):116-21. PubMed ID: 7089017
    [No Abstract]   [Full Text] [Related]  

  • 14. [Evidence of a pharmacokinetic-pharmacodynamic relationship between pharmaco-EEG in healthy subjects after administration of cyclandelate].
    Dimpfel W; Schober F; Wedekind W; Kleinbloesem C; Coors C
    Arzneimittelforschung; 1994 Sep; 44(9):999-1004. PubMed ID: 7986255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liquid chromatographic method for the determination of 3,4-dihydroxyphenylethylene glycol and 3,4-dihydroxymandelic acid in plasma.
    Eriksson BM; Persson BA
    J Chromatogr; 1987 Jan; 386():1-9. PubMed ID: 3104378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation into 3.5.5-trimethylcyclohexyl mandelate (cyclospasmol).
    EIJKEL G; ERNSTING MJ; REKKER RF; NAUTA WT
    Pharm Weekbl; 1956 Feb; 91(3):81-90. PubMed ID: 13310218
    [No Abstract]   [Full Text] [Related]  

  • 17. Simultaneous determination of mandelic acid enantiomers and phenylglyoxylic acid in urine by high-performance liquid chromatography with precolumn derivatization.
    Wang JZ; Wang XJ; Tang YH; Shen SJ; Jin YX; Zeng S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Aug; 840(1):50-5. PubMed ID: 16782414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclandelate and a number of its metabolites inhibit discocyte-echinocyte transformations of human erythrocytes.
    Van den Hoven WE; Hall DW; Burns JW
    Br J Clin Pract Suppl; 1984; 34():26-30. PubMed ID: 6430318
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of cyclandelate on diabetic peripheral neuropathy.
    Canal N; Comi G; Marchettini P; Pozza G
    Br J Clin Pract Suppl; 1984; 34():62-8. PubMed ID: 6430326
    [No Abstract]   [Full Text] [Related]  

  • 20. Investigation on spasmolytics. VII. The metabolism of 3,5,5-trimethylcyclohexylmandelate (cyclandelate). II.
    ERNSTING MJ; REKKER RF; TERSTEEGE HM; NAUTA WT
    Arzneimittelforschung; 1962 Jun; 12():632-5. PubMed ID: 13890671
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.